Business
DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022
MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments
About this update from Diamedica Therapeutics Inc.
[{"type":"text","content":" MINNEAPOLIS--(BUSINESS WIRE)--\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its second quarter 2022 financial results will be released after the markets close on Wednesday, August 10th. DiaMedica will host a live conference call on Thursday, August 11th at 7:00 AM Central Time to provide a business update and discuss financial results.\n\nConference Call details:\n\n\n\nDate:\n\n\n\nThursday, August 11, 2022\n\n\n\n\n\nTime:\n\n\n\n7:00 AM CT / 8:00 AM ET\n\n\n\n\n\nWeb access:\n\n\n\nhttps://events.q4inc.com/attendee/328637791\n\n\n\n\n\nDial In:\n\n\n\n(888) 440-4368\n\n\n\n\n\nConference ID:\n\n\n\n4814247\n\n\n\n\nInterested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until August 18, 2022, by dialing (800) 770-2030 (US Toll Free) and entering the replay passcode: 4814247.\n\nAbout DiaMedica Therapeutics Inc.\n\nDiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant form of the human tissue kallikrein-1 protein (KLK1), an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit our website at www.diamedica.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220804005064/en/\n\nScott Kellen\nChief Financial Officer\nPhone: (763) 496-5118\[email protected]\n\nPaul Papi\nCorporate Communications\nPhone: 617-899-5941\[email protected]\n\nSource: DiaMedica Therapeutics Inc.","length":5258,"tagName":"div"}]